Business Development: Partnering with Teva Neuroscience Canada
Teva Neuroscience has a history of partnering with companies to leverage its R&D and commercial capabilities to advance the company’s growth. Teva Neuroscience aims to be a leader in neurology.
From a global perspective, Teva has formed several key partnerships to further research in neurology and continues to seek opportunities to extend the current competencies to other areas in neurology.
As part of the commitment to furthering the treatment of MS, Teva partnered with Active Biotech, a Swedish company with a potential breakthrough oral medication for the treatment of Multiple Sclerosis. The product, laquinimod, is in the final phase of clinical trials.
Teva Neuroscience Canada and Teva Pharmaceuticals Ltd are seeking in-licensing or collaborative opportunities at any stage of development in the following therapeutic areas:
- Multiple sclerosis and other neurologic conditions
- Auto-immune
- Oncology
In Canada, Teva Neuroscience signed an agreement with Endo Pharmaceuticals for the right to commercialize FROVA®, a novel migraine treatment, in Canada. Teva Neuroscience is an excellent choice for a partner as we:
- Are committed to partnering
- Are structured in a manner which enhances communication and results
- Have a proven track record for success
- Are open to various deal structures